1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
JiangSu WuZhong Pharmaceutical Development Co., Ltd.

JiangSu WuZhong Pharmaceutical Development Co., Ltd.

600200.SS
JiangSu WuZhong Pharmaceutical Development Co., Ltd.CN flagShanghai Stock Exchange
0.29
CNY
-0.03
- -
206.16MMarket Cap
JiangSu WuZhong Pharmaceutical Development Co., Ltd.
600200.SS
(Shanghai Stock Exchange)

Recent

price

0.29

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
3.65
5.43
6.15
5.96
6.21
4.88
4.59
5.82
4.11
2.38
2.94
2.62
2.34
2.92
3.11
2.27
1.45
Revenue per Share
0.02
0.05
0.05
0.08
0.08
0.06
0.08
0.11
0.19
-0.4
0.09
-0.71
0.03
-0.11
-0.1
0.1
- -
Basic EPS, GAAP
0.17
-0.3
-0.69
0.49
0.16
-0.64
-0.03
0.81
-0.04
0.13
-0.37
-0.64
0.56
0.02
-0.4
-0.44
-0.04
Free Cash Flow per Basic Share
0.06
0.06
0.16
0.22
0.18
0.2
0.22
0.13
0.09
0.11
0.07
0.09
0.08
0.1
0.09
0.1
0.08
Dividend per Share
1.1
1.16
1.18
1.27
1.32
1.36
1.46
1.52
1.6
1.16
1.23
0.53
0.49
0.43
0.31
0.42
0.35
Book Value per Share
1.27
1.34
1.36
1.37
1.47
1.6
2.45
3.49
3.28
3.02
2.91
2.38
2.23
2.34
2.12
2.12
2.04
Tangible Book Value per Share
633
623
630
624
624
628
638
686
719
714
717
713
757
693
719
705
710
Basic Weighted Avg Shares
2,309
3,384
3,875
3,723
3,875
3,066
2,928
3,989
2,960
1,702
2,110
1,872
1,775
2,026
2,240
1,599
1,028
Sales/Revenue/Turnover
0.61
1.41
1.27
2.89
4.88
5.47
1.66
1.81
4.43
-2.13
-0.15
-1.6
-1.23
-0.77
-1.12
8.01
15.28
Operating Margin (%)
38
40
38
40
41
47
58
70
85
89
87
83
50
48
46
50
- -
Depreciation Expense
15
29
31
47
51
41
49
72
133
-286
65
-506
23
-76
-72
70
2
Net Income, GAAP
30.87
24.67
26.84
34.57
37.85
34.68
26.26
- -
26.31
- -
20.09
- -
47.4
- -
- -
- -
20.46
Effective Tax Rate (%)
0.63
0.87
0.8
1.26
1.3
1.33
1.68
1.8
4.5
-16.78
3.06
-27.06
1.28
-3.76
-3.21
4.41
0.16
Profit Margin (%)
75
672
709
478
433
627
1,403
1,085
1,042
627
614
1,084
989
874
622
948
893
Working Capital
20
189
327
258
235
340
426
88
88
87
115
230
168
165
141
195
195
LT Debt
890
992
1,010
1,008
1,068
1,139
1,702
2,968
2,931
2,408
2,363
1,852
1,877
1,824
1,761
1,889
1,848
Total Equity
0.63
2.13
1.62
2.86
4.76
4.06
1.16
- -
2.44
- -
-0.08
- -
-0.36
- -
- -
- -
- -
Return on Invested Capital (%)
2.37
3.2
2.41
2.59
1.63
1.78
3.01
- -
7.65
- -
5.89
- -
3.44
- -
- -
- -
7.25
Return on Capital (%)
2.11
4.12
4.2
6.1
6.25
4.87
5.5
7.28
12.12
-28.8
7.54
-80.35
6.07
-22.84
-27.69
27.22
0.65
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
1,452
1,414
1,373
LT Borrowings
181
203
182
LT Finance Leases
14
13
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
712
712
712
Market Capitalization
6,736
3,757
1,790

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
2,753
2,755
2,651
Cash, Cash Equivalents & STI
1,152
168
110
Accounts Receivable, Net
1,296
2,171
2,140
Inventories
94
95
78
Total Current Liabilities
1,805
1,865
1,758
Payables & Accruals
- -
- -
- -
ST Debt
1,452
1,414
1,373
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.36%
-3.86%
7.24%
Free Cash Flow
-594.15%
-454.71%
8.28%
Net Income, GAAP
-191.4%
-325.72%
-197.97%
Sales/Revenue/Turnover
-3.3%
-4.08%
-28.64%
Total Cash Common Dividend
-3.62%
5.67%
-0.09%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
612
489
403
737
2,240
2024
425
503
441
-49
1,599
2025
317
319
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.04
- -
- -
- -
-0.1
2024
0.01
- -
- -
- -
0.1
2025
-0.1
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.02
- -
- -
- -
0.09
2024
0.03
- -
- -
- -
0.1
2025
0.02
- -
- -
- -
- -
Similar Companies
Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)
Core One Labs Inc. (COOL.CN)
CRISPR Therapeutics AG (CRSP)
Acer Therapeutics Inc. (ACER)
NovAccess Global Inc. (XSNX)
NewAmsterdam Pharma Company N.V. (NAMSW)
Business
JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS) develops, manufactures and markets pharmaceutical products; provides medical cosmetology services and investment activities in the medical and health industry; and engages in chemical and real estate businesses primarily in China. Founded in 1994 and headquartered in Suzhou, Jiangsu Province, the company operates through its wholly-owned subsidiary Jiangsu Wuzhong Pharmaceutical Group Corporation, which maintains an integrated pharmaceutical chain covering research, development, production and sales of chemical pharmaceutical preparations, chemical raw materials and modern traditional Chinese medicines focused on anti-virus and anti-infection drugs, immune regulation therapies, anti-tumor medications, digestive system treatments and cardiovascular products; it has earned recognition as a National Contract Abiding and Trustworthy Enterprise, Jiangsu High and New Technology Enterprise and top ranking in China's chemical pharmaceutical industry strengths. In medical cosmetology, it holds a strategic stake in Chengdu Shang-li Aesthetic Co., Ltd., which distributes exclusive China agency rights for high-end hyaluronic acid injection fillers from South Korea's Humedix and pursues R&D, production and sales of medical aesthetics via overseas technology licensing and independent development, while expanding into functional skincare and related equipment through mergers, acquisitions and partnerships to build a comprehensive platform; its investment arm, Jiangsu Wuzhong Pharmaceutical Industry Investment Co., Ltd., participates in medical one-health industry funds. The company prioritizes high-end generic drugs, first generics, consistency evaluations for injections and tablets, and innovative drug R&D as part of its 2020-2024 strategic plan to form a big health industry cluster; recent developments include a subsidiary arbitration filing against Regen Biotech seeking contract validation or 1.6 billion yuan compensation, alongside entry into a delisting arrangement period on the Shanghai Stock Exchange starting December 9, 2025, due to falsified financial information and share price declines below thresholds, marking a significant operational shift with trading resumption during the period and full delisting thereafter.